Kenneth S. Canfield

Ken Canfield's practice focuses primarily on patent litigation, including pre-suit investigations, discovery, motion practice, claim construction, trial, post-trial proceedings, and appeal. He has taken a leading role in managing the day-to-day activities in litigations. Ken's technological areas of practice include electronics, computers, software, physics, and related fields. In addition, he has worked in the medical device and pharmaceutical fields.

Ken's recent representations include defending companies accused of infringing patents relating to satellite broadcast technology, stent technology, leveraged exchange-traded products, and pharmaceuticals. He also represents brand-name pharmaceutical companies in Hatch-Waxman litigation. His representations in this area include litigations concerning Thalomid® (a treatment of multiple myeloma and erythema nodosum leprosum), Revlimid®, Xyrem® (a treatment for symptoms of narcolepsy), Lotronex® (a female irritable-bowel-syndrome treatment), Kuvan® (a treatment for phenylketonuria), OxyCodone® (a pain reliever), and Androgel® (a testosterone replacement therapy). [1]